Cipher Pharma Acquires INNOCUTIS Holdings

Client Type: Private Company

We represented INNOCUTIS Holdings in its acquisition by Cipher Pharma for $45.5 million. INNOCUTIS is a pharmaceutical company specializing in the development and commercialization of therapies focused on medical treatment of dermatological conditions. Cipher Pharmaceuticals (NASDAQ: CPHR; TSX: CPH) is a rapidly growing specialty pharmaceutical company.

We represented INNOCUTIS Holdings in its acquisition by Cipher Pharma for $45.5 million. INNOCUTIS is a pharmaceutical company specializing in the development and commercialization of therapies focused on medical treatment of dermatological conditions. Cipher Pharmaceuticals (NASDAQ: CPHR; TSX: CPH) is a rapidly growing specialty pharmaceutical company.